Find policies, billing codes, payers, states, and providers
HCPCS J3111: Injection, romosozumab-aqqg, 1 mg
HCPCS Level II code J3111 denotes a 1 mg injection of romosozumab-aqqg, a monoclonal antibody used to treat osteoporosis by promoting bone formation and reducing resorption. As a high-cost biologic therapy administered by injection, this code is relevant for outpatient infusion centers, physician offices, and specialty practices managing osteoporosis.
Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage policies, prior authorization requirements, and site-of-care stipulations for romosozumab vary across these payers and can affect access and billing workflows.
Readers will find a concise overview of the clinical context for romosozumab, the billing implications of using HCPCS Level II code J3111, and what to expect in payer interactions and claims adjudication. The publication covers benchmark considerations, relevant policy updates affecting injectable biologics, and operational notes for outpatient settings. Data not available in the input will be noted explicitly where applicable.
Customize your policy alerts
Sign up for hcpcs J3111 policy alerts
Get alerted when payer policies referencing J3111 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J3111 represents an injection of romosozumab-aqqg, billed per 1 mg. This code describes administration of a monoclonal antibody therapy used in the treatment of osteoporosis by inhibiting sclerostin to increase bone formation and decrease bone resorption.
Service type: Drug administration (injectable biologic)
Typical site of service: Outpatient infusion/injection center or physician office
Data not available in the input.